✨ Free AI Report
Galecto, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Galecto, Inc.
Company Research

Galecto, Inc.: Business Overview, Financials & Competitive Analysis

Galecto is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer and liver diseases, with an increasing emphasis on hematological malignancies. The company completed the acquisit...

Analyst-debate audio for Galecto, Inc.

AskCyborg analysts argue the bull and bear cases for Galecto, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Clinical-stage biotech with strong balance sheet and focused mutCALR pipeline addressing significant unmet need in rare...

Read the full analyst-debate transcript →
Industry Oncology Drugs
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Galecto, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Galecto, Inc. Overview

Pro stress-test →

Galecto is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer and liver diseases, with an increasing emphasis on hematological malignancies. The company completed the acquisition of Damora Therapeutics in November 2025, and announced a name change to Damora Therapeutics in March 2026, repositioning its focus toward advancing disease-modifying biologics for blood cancers driven by mutant calreticulin.

Strategic Profile

Pro stress-test →

A concurrent private placement of Series C non-voting convertible preferred stock in November 2025 resulted in approximately $284.9 million in gross proceeds and is expected to fund operations into 2029. With multiple programs with best-in-class potential on track to enter clinical development in 2026, the company aims to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes.

Competitive Landscape

Pro stress-test →

Galecto is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. Direct competitors in the mutCALR space are limited; broader competitors include oral FLT3 and menin inhibitors (ruxolitinib, fedratinib, and investigational menin inhibitors) for MPN/ET treatment. Galecto's antibody-based approach targets an underserved patient population with no approved disease-modifying mutCALR therapies.

Industry Context

Galecto, Inc. operates in Oncology Drugs.

Key facts

Founded: 2011 · Headquarters: Boston, Massachusetts · Employees: 30 · Revenue: $0 · Market cap: N/A

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Galecto, Inc..

  • Strategic pivot (November 2025 to March 2026): Acquired Damora Therapeutics and rebranded to focus on mutCALR-driven myeloproliferative neoplasms (ET and MF), moving away from fibrosis/IPF programs
  • Well-capitalized through 2029: ~$285M private placement (November 2025) enables advancement of DMR-001 through Phase 1 proof-of-concept expected in 2027, plus DMR-002 and DMR-003 into Phase 1
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • October 2024Completed strategic review to focus on oncology and liver disease; acquired global rights to BRM-1420 (ENL-YEATS/FLT3 inhibitor) from Bridge Medicines
  • November 2025Completed acquisition of Damora Therapeutics for mutCALR-targeted therapies; concurrent $284.9M Series C private placement
  • +1 moreTrack every material event for Galecto, Inc. as it happens. Explore monitoring →
Get alerted when Galecto, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Ruxolitinib (Jakafi)JAK inhibitor for myelofibrosis and polycythemia vera→Fedratinib (Inrebic)JAK2/FLT3 inhibitor for myelofibrosis→Menin inhibitorsInvestigational menin inhibitors for AML and MPN treatment→

Compare Galecto, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Galecto, Inc. operates in Oncology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology Drugs research →
NEW · MCP server

Ask your AI assistant about Galecto, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Galecto, Inc. and its top competitor on Cyborg Score”
“What did Galecto, Inc. do this quarter?”
“Is Galecto, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Galecto, Inc. do?+
Galecto is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer and liver diseases, with an increasing emphasis on hematological malignancies. The company completed the acquisit...
What is Galecto, Inc.'s Cyborg Score?+
Galecto, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Galecto, Inc.'s main competitors?+
Named competitors include Ruxolitinib (Jakafi), Fedratinib (Inrebic), Menin inhibitors. The full competitive landscape is in the AskCyborg report.
How can I get the full Galecto, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Galecto, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Galecto, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.